Therapeutic effect of paroxetine on patients with early poststroke depression and the serum interleukins
10.3969/j.issn.1672-5921.2011.05.003
- Author:
Juan YANG
1
Author Information
1. Department of Neurology
- Publication Type:Journal Article
- Keywords:
Depression;
Interleukin-1 beta;
Interleukin-6;
Paroxetine;
Stroke;
Treatment outcome
- From:
Chinese Journal of Cerebrovascular Diseases
2011;8(5):235-238
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the effect of paroxetine on the levels of serum interleukin-1 beta (IL-1β) and IL-6 in patients with early poststroke depression (PSD) and the degree of improvement of the depressive symptoms. Methods: Two hundred twenty-three consecutive patients with stroke within 72 hours of symptom onset were included. A total of 42 patients with early PSD whose Hamilton Depression Scale (HAMD) score ≥ 8 within 72 hours of onset were selected. They were randomly allocated into paroxetine treatment group (n = 20) and control group (n = 22). The patients in the treatment group were treated with paroxetine 20 mg/d at the time point of 72 hours, and the course of treatment was ≥ 3 months. The other treatments were the same in both groups. The serum concentrations of IL-1β and IL-6 at 72 hours, 1 and 3 months after onset, as well as the HAMD scores at all time points were compared. Results: Circled digit oneThere was no difference in the HAMD scores between the 2 groups at 72 hours after onset. The HAMD score in the treatment group was lower than that in the control group at the same time period 1 and 3 months after treatment. There were significant difference (P < 0.01). There was no significant difference in the HAMD scores between the 2 groups 1 and 3 months after treatment. Circled digit twoThere was no significant difference in serum IL-1β and IL-6 at 72 hours after onset in both groups of patients. The IL-1β and IL-6 in the treatment group were lower than those in the control group at the same time 1 and 3 months after treatment. There were significant difference (P < 0.01). IL-1β and IL-6 reached the peaks at 1 month after treatment in both groups, and began to decrease at 3 months, but the control group was still higher than the level at 72 hours (P < 0.01), and the treatment group was decreased to the level at 72 hours. Conclusion: The increased serum IL-1β and IL-6 concentrations may be ralated to the onset of patients with early PSD. Paroxetine may improve the depressive symptoms of patients by the interference of the serum IL-1β and IL-6.
